English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   99m Tc-Rituximab is a new specific radiopharmaceutical that binds to the CD20 receptor which is highly expressed on the surface of B cells. We conducted a study in which  99m Tc-Rituximab was compared with filtered  99m Tc-sulfur colloid (fTcSC) for sentinel lymph node (SLN) detection in patients with breast cancer.    Method  The study is divided into three parts. 1. Initially, 25 patients were selected for an internal controlled trial to received both  99m Tc-Rituximab and fTcSC, the interval time is separated by ≥2 days. 2. Then, 91 patients were selected for a randomized controlled trial (41 and 50 patients in the  99m Tc-Rituximab and fTcSC groups, respectively). All patients were administered either agent at the 6- and 12-o’ clock positions by subareolar injection technique. SLN mapping was then performed 2 h after injection. 3. Serial dynamic images were further acquired for 2 h in 31 patients (22 and 9 patients from  99m Tc-Rituximab and fTcSC cohorts, respectively).    Results  The identification rate of lymphoscintigraphy and SLNB in all and axilla regions for  99m Tc-Rituximab and  99m Tc-SC were 98.5% vs 98.7, 100% vs 98.4%, respectively. The mean number of SLNs identified by  99m Tc-Rituximab and fTcSC was respectively 2.72 and 3.28, with a significant difference of  P  = 0.013 (paired sample t-test). The difference exists in the internal mammary and clavicular area, not in the axillary. The mean number of axillary sentinel lymph node biopsy (SLNB) for  99m Tc-Rituximab and fTcSC was 2.95 vs 3.14, respectively, and no significant difference existed.  99m Tc-Rituximab also exhibited a significantly faster injection site clearance rate when compared with fTcSC (0.193 ± 0.057 h − 1  vs 0.021 ± 0.007 h − 1 , respectively).    Conclusion  No significant difference was observed in identification rate and number of axillary SLN imaging and SLNB, between the two tracers. Compared to fTcSC,  99m Tc-Rituximab based imaging demonstrated a fewer number of secondary lymph nodes and had faster injection site clearance rate.    Trial registration  www.chictr.org.cn,  ChiCTR1900024990  (retrospectively registered August 6, 2019).

Comparative research on 99mTc-Rituximab and 99mTc-sulfur colloid in sentinel lymph node imaging of breast cancer